Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Completed · Phase 1

Conditions studied: Corneal Neovascularization

In brief

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Key facts

Study ID

NCT00769145

Run by

University of Miami

People needed

5

Starts

2008-10-01

Expected to finish

2012-03-01

Last updated by the study team

2017-07-11

Who can join

Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be eligible if the following criteria are met:
• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age > 18 years
• Patient related considerations
• All patients of both genders will be considered for enrollment.
• Disease related considerations
• Patients meeting accepted criteria for undergoing corneal transplantation will be considered if peripheral corneal neovascularization exists in 2 or more contiguous clock hours

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy (positive pregnancy test)
• Women seeking to become pregnant
• Lactating women
• Prior enrollment in the study
• Prior glaucoma surgery in the region of the corneal neovascularization
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
• Participation in another simultaneous medical investigation or trial

Where it is running

• Bascom Palmer Eye Institute — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.